PL3233852T3 - Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania - Google Patents

Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania

Info

Publication number
PL3233852T3
PL3233852T3 PL15810660T PL15810660T PL3233852T3 PL 3233852 T3 PL3233852 T3 PL 3233852T3 PL 15810660 T PL15810660 T PL 15810660T PL 15810660 T PL15810660 T PL 15810660T PL 3233852 T3 PL3233852 T3 PL 3233852T3
Authority
PL
Poland
Prior art keywords
indoles
pyrido
tetrahydro
estrogen receptor
receptor modulators
Prior art date
Application number
PL15810660T
Other languages
English (en)
Inventor
Simon Charles Goodacre
Sharada Labadie
Jun Liang
Daniel Fred Ortwine
Nicholas Charles Ray
Xiaojing Wang
Jason ZBIEG
Birong Zhang
Kwong Wah LAI
Jiangpeng LIAO
Zhiguo Liu
John Sui-Man WAI
Tao Wang
Jun Li
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3233852T3 publication Critical patent/PL3233852T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL15810660T 2014-12-18 2015-12-17 Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania PL3233852T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18
US201562110998P 2015-02-02 2015-02-02
US201562142077P 2015-04-02 2015-04-02
PCT/EP2015/080119 WO2016097072A1 (en) 2014-12-18 2015-12-17 TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP15810660.9A EP3233852B1 (en) 2014-12-18 2015-12-17 Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
PL3233852T3 true PL3233852T3 (pl) 2020-12-14

Family

ID=54850193

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15810660T PL3233852T3 (pl) 2014-12-18 2015-12-17 Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania

Country Status (33)

Country Link
US (4) US9980947B2 (pl)
EP (2) EP3233852B1 (pl)
JP (4) JP6679147B2 (pl)
KR (4) KR102785474B1 (pl)
CN (6) CN118005631A (pl)
AU (3) AU2015367509B2 (pl)
BR (1) BR112017007662B1 (pl)
CA (1) CA2963736A1 (pl)
CL (2) CL2017000814A1 (pl)
CO (1) CO2017003070A2 (pl)
CR (1) CR20170250A (pl)
DK (1) DK3233852T3 (pl)
EA (1) EA032311B1 (pl)
ES (1) ES2819448T3 (pl)
HR (1) HRP20201396T1 (pl)
HU (1) HUE050466T2 (pl)
IL (5) IL301960B2 (pl)
LT (1) LT3233852T (pl)
MA (1) MA53837A (pl)
MX (3) MX376763B (pl)
MY (1) MY198354A (pl)
NZ (1) NZ769496A (pl)
PE (1) PE20171330A1 (pl)
PH (1) PH12017501140A1 (pl)
PL (1) PL3233852T3 (pl)
PT (1) PT3233852T (pl)
RS (1) RS60824B1 (pl)
SG (3) SG10202100799PA (pl)
SI (1) SI3233852T1 (pl)
TW (5) TWI874834B (pl)
UA (1) UA122868C2 (pl)
WO (1) WO2016097072A1 (pl)
ZA (1) ZA202108745B (pl)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
KR102785474B1 (ko) 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR102710603B1 (ko) * 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
SMT202300018T1 (it) 2015-12-09 2023-03-17 Univ Illinois Downregolatori del recettore degli estrogeni a base di benzotiofene
CN109362222B (zh) * 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
LT3416962T (lt) 2016-02-15 2021-07-12 Sanofi 6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
US20170362228A1 (en) * 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN107543871A (zh) * 2016-06-29 2018-01-05 重庆华邦胜凯制药有限公司 分离测定帕布昔利布中间体z1及其有关物质的方法
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018019793A1 (en) * 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
KR20230152814A (ko) * 2016-09-27 2023-11-03 래디어스 파마슈티컬스, 인코포레이티드 난소암을 치료하기 위한 방법
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
TWI735681B (zh) * 2016-10-24 2021-08-11 瑞典商阿斯特捷利康公司 化合物
US10774081B2 (en) * 2016-10-28 2020-09-15 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Indolo substituted piperidine compound as estrogen receptor down-regulator
ES3039455T3 (en) * 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
EA037533B9 (ru) * 2016-12-16 2021-05-27 Астразенека Аб 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
PT3494116T (pt) * 2017-01-30 2020-01-28 Astrazeneca Ab Moduladores de recetores de estrogénio
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US11236088B2 (en) 2017-11-14 2022-02-01 Kind Pharmaceutical Heterocyclic compounds and their application in medicine
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
IL276152B2 (en) 2018-01-22 2023-12-01 Radius Pharmaceuticals Inc Estrogen receptor-modulating compounds
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CA3109090A1 (en) * 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
JP7413363B2 (ja) 2018-09-07 2024-01-15 サノフイ メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
KR20210131316A (ko) * 2019-02-27 2021-11-02 밀레니엄 파머슈티컬스 인코퍼레이티드 Sumo-활성화 효소 저해제 및 관문 저해제의 투여
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
EP3983384B1 (en) * 2019-06-17 2023-10-11 UCB Pharma GmbH N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
MX2022000279A (es) * 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
JP7614169B2 (ja) 2019-07-22 2025-01-15 ラジウス ファーマシューティカルズ，インコーポレイテッド エストロゲン受容体調節化合物
CA3148221A1 (en) 2019-08-06 2021-02-11 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
US20220370625A1 (en) * 2019-09-19 2022-11-24 Totus Medicines Inc. Therapeutic conjugates
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20220113695A (ko) 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
WO2021127039A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
BR112022011827A2 (pt) 2019-12-20 2022-08-30 C4 Therapeutics Inc Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
WO2021143822A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 并环酰亚胺类衍生物、其制备方法及其在医药上的应用
TW202140475A (zh) * 2020-01-16 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
CN115175679A (zh) 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
WO2021213358A1 (zh) * 2020-04-21 2021-10-28 江苏先声药业有限公司 含硼化合物及其应用
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
WO2021214253A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
TWI800827B (zh) * 2020-05-12 2023-05-01 美商建南德克公司 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌
AU2021269612A1 (en) * 2020-05-15 2023-01-05 Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrrolidine compound and use thereof
WO2021249533A1 (zh) * 2020-06-12 2021-12-16 江苏先声药业有限公司 雌激素受体调节剂化合物及其用途
KR20250171413A (ko) 2020-06-30 2025-12-08 제넨테크, 인크. 치환된 페닐 또는 피리디닐 모이어티를 갖는 serd 트리시클릭 화합물의 제조 방법
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED DEGRADATION OF RET
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
WO2022166983A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
JP2024506385A (ja) 2021-02-16 2024-02-13 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022261250A1 (en) 2021-06-08 2022-12-15 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
CN117813288A (zh) * 2021-07-15 2024-04-02 西藏海思科制药有限公司 芳氨基衍生物雌激素受体调节剂及其用途
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
EP4412991A1 (en) * 2021-10-08 2024-08-14 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists
CN118119620A (zh) * 2021-11-12 2024-05-31 南京再明医药有限公司 用于治疗肿瘤的药物组合及其应用
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
US12410155B2 (en) 2021-12-28 2025-09-09 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Salt form and crystal form of tetrahydrocyclohepta indazole compound
CN116804008A (zh) * 2022-03-24 2023-09-26 烟台创和生物科技有限公司 雌激素受体降解剂及其制备方法和应用
EP4514792A1 (en) 2022-04-28 2025-03-05 F. Hoffmann-La Roche AG Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024017131A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
CN115109058B (zh) * 2022-07-27 2023-04-07 黑龙江中医药大学 一种用于治疗胃癌的药物及其制备方法
JP2025525917A (ja) 2022-08-03 2025-08-07 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔタンパク質を調節するための化合物
WO2024039860A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
AU2023324854A1 (en) * 2022-08-19 2025-01-30 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2024042163A1 (en) * 2022-08-25 2024-02-29 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
CN120112288A (zh) * 2022-10-28 2025-06-06 南京再明医药有限公司 用于治疗肿瘤的药物组合、药物组合物及其用途
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
CN115894485B (zh) * 2023-03-03 2023-06-27 山东绿叶制药有限公司 杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
US11773092B1 (en) 2023-03-27 2023-10-03 King Faisal University Pyrido[3,4-b]indol-1-one compounds as antibacterial agents
EP4709386A1 (en) 2023-05-11 2026-03-18 Astrazeneca AB Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途
CN118791392B (zh) * 2024-06-18 2026-02-17 华中科技大学 一种合成依拉司群的方法及中间体化合物
US20260008798A1 (en) 2024-07-02 2026-01-08 Hoffmann-La Roche Inc. Palladium catalyzed synthesis of aminoaldehyde intermediates

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE398789C (de) 1923-03-03 1924-07-15 L V Kramolin Verfahren und Einrichtung zur Verhinderung des Mithoerens beim Telephon- und Telegraphenverkehr mittels elektrischer Wellen und zum Vielfachverkehr mittels elektromagnetischer Wellen
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
SE455604B (sv) 1982-06-29 1988-07-25 Stiftelsen Ind Organisk Elektr Sett att framstella fenetylaminer medelst elektrokemisk reduktion
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
EP1347759B1 (en) 2000-12-08 2005-06-29 Smithkline Beecham Corporation Antibacterial compounds
JP4220779B2 (ja) 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
EP1670314A4 (en) 2003-09-05 2009-02-25 Sequella Inc METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
MXPA06010543A (es) * 2004-03-15 2007-03-26 Ptc Therapeutics Inc Derivados de carbolina utiles en la inhibicion de la angiogenesis.
US20080103164A1 (en) 2004-08-02 2008-05-01 Kristjan Gudmundsson Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
AU2009242279B2 (en) 2008-04-29 2012-08-30 Novartis Ag Spiro-indole derivatives for the treatment of parasitic diseases
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
WO2010015815A2 (en) 2008-08-05 2010-02-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
WO2010114900A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-piperidine compounds
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
WO2010138685A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120157401A1 (en) * 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20130171103A1 (en) 2010-05-27 2013-07-04 Ptc Therapeutics, Inc. Methods for treating viral conditions
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CN103313989B (zh) * 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
JP6112625B2 (ja) 2011-12-14 2017-04-12 セラゴン ファーマシューティカルズ，インク． フッ素化したエストロゲン受容体モジュレーターおよびその使用
JP6117906B2 (ja) 2012-03-23 2017-04-19 ノバルティス アーゲー スピロインドロンおよびこれらの中間体を調製するための化学プロセス
HUE036985T2 (hu) 2012-03-23 2018-08-28 Codexis Inc Biokatalizátor és eljárások triptamin és triptamin-analógok származékainak szintetizálására
DE102012209622A1 (de) 2012-06-08 2013-12-12 Robert Bosch Gmbh Zahnradmaschine mit hydrodynamisch und hydrostatisch gelagertem Lagerzapfen
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
MX361157B (es) * 2012-08-30 2018-11-28 Hoffmann La Roche Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso.
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
TWI653235B (zh) 2013-05-28 2019-03-11 阿斯特捷利康公司 作為抗癌劑之吲哚衍生物
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2015066019A1 (en) 2013-10-28 2015-05-07 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
WO2015082990A1 (en) 2013-12-06 2015-06-11 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
EP3233818A1 (en) 2014-12-18 2017-10-25 F. Hoffmann-La Roche AG Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
KR102785474B1 (ko) 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR102710603B1 (ko) 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途

Also Published As

Publication number Publication date
TWI784255B (zh) 2022-11-21
IL287326A (en) 2021-12-01
AU2015367509B2 (en) 2020-01-02
SI3233852T1 (sl) 2020-10-30
ES2819448T3 (es) 2021-04-16
IL311006A (en) 2024-04-01
TW202534076A (zh) 2025-09-01
BR112017007662A8 (pt) 2021-10-05
CN112375078B (zh) 2023-12-19
EP3760623B1 (en) 2026-03-18
SG10202100799PA (en) 2021-03-30
MX376763B (es) 2025-03-07
US9980947B2 (en) 2018-05-29
US20250114338A1 (en) 2025-04-10
JP2022088416A (ja) 2022-06-14
CL2019000431A1 (es) 2019-07-12
JP7446348B2 (ja) 2024-03-08
CN107108611B (zh) 2020-09-25
US10966963B2 (en) 2021-04-06
CN118005631A (zh) 2024-05-10
MA53837A (fr) 2021-11-10
IL301960A (en) 2023-06-01
JP7792942B2 (ja) 2025-12-26
CN112375078A (zh) 2021-02-19
TW202323253A (zh) 2023-06-16
US20230045776A9 (en) 2023-02-09
JP2020073493A (ja) 2020-05-14
AU2021200352A1 (en) 2021-03-18
KR20250044940A (ko) 2025-04-01
AU2021200352B2 (en) 2022-12-15
HUE050466T2 (hu) 2020-12-28
US20180235945A1 (en) 2018-08-23
JP2024028785A (ja) 2024-03-05
CA2963736A1 (en) 2016-06-23
EP3760623A1 (en) 2021-01-06
HRP20201396T1 (hr) 2020-11-27
EP3760623C0 (en) 2026-03-18
IL251370B (en) 2020-02-27
JP7128169B2 (ja) 2022-08-30
TWI874834B (zh) 2025-03-01
PH12017501140A1 (en) 2018-03-05
NZ730448A (en) 2021-02-26
KR102559719B1 (ko) 2023-07-26
MX395013B (es) 2025-03-24
TW201636348A (zh) 2016-10-16
BR112017007662A2 (pt) 2017-12-19
IL287326B1 (en) 2023-05-01
EA201791239A1 (ru) 2017-10-31
SG11201704401TA (en) 2017-07-28
IL301960B2 (en) 2024-08-01
CR20170250A (es) 2017-07-19
US12233052B2 (en) 2025-02-25
TWI875674B (zh) 2025-03-01
IL287326B2 (en) 2023-09-01
NZ769496A (en) 2023-09-29
IL251370A0 (en) 2017-05-29
EP3233852B1 (en) 2020-07-15
SG10201913913VA (en) 2020-03-30
IL301960B1 (en) 2024-04-01
IL270653B (en) 2021-12-01
CN107108611A (zh) 2017-08-29
CN112457310A (zh) 2021-03-09
MX2022007975A (es) 2022-07-05
PT3233852T (pt) 2020-09-10
EA032311B1 (ru) 2019-05-31
JP6679147B2 (ja) 2020-04-15
KR20250044939A (ko) 2025-04-01
LT3233852T (lt) 2020-10-12
WO2016097072A1 (en) 2016-06-23
AU2015367509A1 (en) 2017-04-13
CL2017000814A1 (es) 2017-12-29
CO2017003070A2 (es) 2017-07-11
BR112017007662B1 (pt) 2021-11-03
RS60824B1 (sr) 2020-10-30
KR20230113416A (ko) 2023-07-28
UA122868C2 (uk) 2021-01-13
TW202506643A (zh) 2025-02-16
MY198354A (en) 2023-08-28
AU2020200407A1 (en) 2020-02-13
JP2017538725A (ja) 2017-12-28
US20160175289A1 (en) 2016-06-23
EP3233852A1 (en) 2017-10-25
EA201791239A8 (ru) 2019-01-31
MX2020003532A (es) 2020-07-29
US20210236473A1 (en) 2021-08-05
DK3233852T3 (da) 2020-09-14
AU2020200407B2 (en) 2021-04-08
KR102785474B1 (ko) 2025-03-26
PE20171330A1 (es) 2017-09-13
HK1243074A1 (zh) 2018-07-06
KR20170097651A (ko) 2017-08-28
ZA202108745B (en) 2024-10-30
TWI699363B (zh) 2020-07-21
TW202028204A (zh) 2020-08-01
MX2017007489A (es) 2017-10-18
CN117865872A (zh) 2024-04-12
CN112375077A (zh) 2021-02-19

Similar Documents

Publication Publication Date Title
IL287326A (en) Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
IL258363B (en) Tetrahydro-h1-pyrido[4,3-b]indole anti-estrogenic drugs
EP3512842A4 (en) INDOLDER DERIVATIVES AS A DEGRADOR OF THE ESTROGEN RECEPTOR
PL3490565T3 (pl) Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
AU2015367620B2 (en) Unit, device and system for preparing beverage consumptions
IL247250A0 (en) Methods and compositions for modulating estrogen receptor mutants
ZA201605712B (en) Therapeutic combinations with estrogen receptor modulators
EP3169683A4 (en) Functionalised and substituted indoles as anti-cancer agents
EP3224261A4 (en) Opioid receptor modulators
EP3196609A4 (en) Dispersion and supply device and combination weighing device
IL249267A0 (en) Materials containing carbonitrile and their use for selective modulation of the androgen receptor
EP3237102A4 (en) Device for cavitational mixing
PT3157912T (pt) Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações
EP3149380A4 (en) Swivel device
IL252753A0 (en) History of indole and azaindole, their preparation and use
GB201515296D0 (en) Hydrogel compositions, methods for preparing the same and uses thereof
EP3224230A4 (en) Estrogen receptor modulators
WO2015196144A3 (en) Androgen receptor antagonists
HK1259498A1 (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
AU2014900105A0 (en) Skirt Securing Device
HK1233666A1 (en) Fgf21 receptor agonists and uses thereof